761440-78-2

Basic information

• Product Name: Benzenamine, 2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]-
• CAS NO: 761440-78-2
• Molecular Formula: C16H25N3O
• Molecular Weight: 275.394
• Mol File: 761440-78-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzenamine, 2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]-(761440-78-2)
• EPA Substance Registry System: Benzenamine, 2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]-(761440-78-2)

Safety Data

• Hazardous Substances Data: 761440-78-2(Hazardous Substances Data)

Upstream product

• 5004-07-9 4-(1-pyrrolidinyl)piperidine 
• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 761440-23-7 1-(3-methoxy-4-nitro-phenyl)-4-pyrrolidin-1-yl-piperidine 

Downstream Products

• 1089279-95-7 N-(2,6-difluorophenyl)-3-{3-[2-({2-(methyloxy)-4-[4-(1-pyrrolidinyl)-1-piperidinyl]-phenyl}amino)-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl}benzamide 

Relevant articles and documents

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors. This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clinical candidate brigatinib. A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addition to favorable ADME properties. Brigatinib displayed low nanomolar IC50s against native ALK and all tested clinically relevant ALK mutants in both enzyme-based biochemical and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC). Brigatinib represents the most clinically advanced phosphine oxide-containing drug candidate to date and is currently being evaluated in a global phase 2 registration trial.

NOVEL COMPOUNDS

There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.

2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS

Novel pyrimidine derivatives of formula (I), to processes for their production, their use as pharmaceuticals in the treatment of neoplastic diseases, inflammatory and immune system disorders and to pharmaceutical compositions comprising them.